Hepatitis/MASH

In the 2 mg bulevirtide (Gilead Sciences) group, 44% of individuals achieved HDV RNA that was undetectable compared with 70% in the 10 mg group.

Investigators found improvements over the placebo in metabolic dysfunction-associated steatohepatitis without worsening fibrosis across 3 dosing groups.

The test can be performed in settings that operate under the Clinical Laboratory Improvement Amendments waiver, including community pharmacies.

Lindsey P. Sheehan, PharmD, MPA, MBA, discusses ongoing challenges of diagnosing and treating hepatitis C, emphasizing its increased incidence among younger populations and ongoing low rates of diagnosis.

Study investigators hired undercover shoppers, and the results revealed more education is needed on the Syringe Service Program, which provides legal, clean over-the-counter (OTC) needles to whomever seeks them out.

The primary outcome was a 90-day incidence of mortality or liver transplant for individuals who received larsucosterol, compared to the placebo group.

Hepatitis Awareness Month is designed to raise awareness of viral hepatitis and promote testing and vaccination while decreasing the stigma against the virus.

Patients who were formerly incarcerated commonly experience substance use disorder, tuberculosis, hepatitis C, and sexually transmitted diseases

The new indication includes pediatric patients aged 6 years and older who weigh at least 25 kg and have compensated liver disease.

After 48 weeks of treatment with survodutide, patients demonstrated histological improvement, a reduction in liver fat content, and did not experience worsening fibrosis.

In this model, community pharmacists deliver all aspects of treating HCV infection in individuals who inject drugs.

Bepirovirsen is a triple action investigational antisense oligonucleotide and is being evaluated in the B-Well phase 3 clinical trial program for the treatment of chronic hepatitis B.

The results suggest that telemedicine could be used to help improve access for other populations that might be stigmatized, beyond hepatitis C virus and opioid use disorder.

The study investigators said that restricting access to direct-acting antiviral therapy due to alcohol consumption could create unnecessary barriers for those with hepatitis C virus.

Pharmacists can play a crucial role in educating parents and helping remind them about the childhood vaccine schedule, which can be quite complex.

Policy efforts must be put in place to support HCV treatment for all individuals to reduce the disparities in direct-acting antiviral treatment.

The study authors said that further investigation is needed to explore specialized care for mothers and newborns who are affected by hepatitis C infections during pregnancy.

The once-daily therapeutic agent is effective for pediatric patients and pregnant women with HIV.

A significant proportion of patients had negative hepatitis B surface antibody titers, indicating a need for vaccination to ensure protection for patients undergoing hemodialysis.

HCV infection is mostly curable and treated with antiviral medications, which can clear the virus from the body.

Delivery, manufacturing concerns hinder green light from US Agency, but European Medicines Agency approves treatment.

Having scheduled check-ins for an ongoing trial arguably helps patients feel more informed and in charge of their health.

Biosimilars are also expanding rapidly, offering new opportunities for payers, patients, and providers.

Any living person with HIV should be screened for hepatitis B and C upon diagnosis, with annual screenings recommended for those with additional risk factors.

Currently, APHA has a policy on its books that opposes both drug legalization and decriminalization.